Browsing by Subject "PROSTATE-CANCER"

Sort by: Order: Results:

Now showing items 1-20 of 37
  • Kaprio, Tuomas; Hagstrom, Jaana; Fermer, Christian; Mustonen, Harri; Bockelman, Camilla; Nilsson, Olle; Haglund, Caj (2014)
  • Conesa, Ana; Madrigal, Pedro; Tarazona, Sonia; Gomez-Cabrero, David; Cervera Taboada, Alejandra; McPherson, Andrew; Szczesniak, Michal Wojciech; Gaffney, Daniel J.; Elo, Laura L.; Zhang, Xuegong; Mortazavi, Ali (2016)
    RNA-sequencing (RNA-seq) has a wide variety of applications, but no single analysis pipeline can be used in all cases. We review all of the major steps in RNA-seq data analysis, including experimental design, quality control, read alignment, quantification of gene and transcript levels, visualization, differential gene expression, alternative splicing, functional analysis, gene fusion detection and eQTL mapping. We highlight the challenges associated with each step. We discuss the analysis of small RNAs and the integration of RNA-seq with other functional genomics techniques. Finally, we discuss the outlook for novel technologies that are changing the state of the art in transcriptomics.
  • Pittman, Alan M.; Naranjo, Silvia; Jalava, Sanni E.; Twiss, Philip; Ma, Yussanne; Olver, Bianca; Lloyd, Amy; Vijayakrishnan, Jayaram; Qureshi, Mobshra; Broderick, Peter; van Wezel, Tom; Morreau, Hans; Tuupanen, Sari; Aaltonen, Lauri A.; Eva Alonso, M.; Manzanares, Miguel; Gavilan, Angela; Visakorpi, Tapio; Luis Gomez-Skarmeta, Jose; Houlston, Richard S. (2010)
  • Sahu, Biswajyoti; Pihlajamaa, Paivi; Dubois, Vanessa; Kerkhofs, Stefanie; Claessens, Frank; Jänne, Olli A. (2014)
  • Callegari, Elisa; Elamin, Bahaeldin K.; D'Abundo, Lucilla; Falzoni, Simonetta; Donvito, Giovanna; Moshiri, Farzaneh; Milazzo, Maddalena; Altavilla, Giuseppe; Giacomelli, Luciano; Fornari, Francesca; Hemminki, Akseli; Di Virgilio, Francesco; Gramantieri, Laura; Negrini, Massimo; Sabbioni, Silvia (2013)
  • Carstensen, Bendix; Read, Stephanie H.; Friis, Soren; Sund, Reijo; Keskimaki, Ilmo; Svensson, Ann-Marie; Ljung, Rickard; Wild, Sarah H.; Kerssens, Joannes J.; Harding, Jessica L.; Magliano, Dianna J.; Gudbjornsdottir, Soffia; Diabet Canc Res Consortium (2016)
    An excess cancer incidence of 20-25% has been identified among persons with diabetes, most of whom have type 2 diabetes. We aimed to describe the association between type 1 diabetes and cancer incidence. Persons with type 1 diabetes were identified from five nationwide diabetes registers: Australia (2000-2008), Denmark (1995-2014), Finland (1972-2012), Scotland (1995-2012) and Sweden (1987-2012). Linkage to national cancer registries provided the numbers of incident cancers in people with type 1 diabetes and in the general population. We used Poisson models with adjustment for age and date of follow up to estimate hazard ratios for total and site-specific cancers. A total of 9,149 cancers occurred among persons with type 1 diabetes in 3.9 million person-years. The median age at cancer diagnosis was 51.1 years (interquartile range 43.5-59.5). The hazard ratios (HRs) (95% CIs) associated with type 1 diabetes for all cancers combined were 1.01 (0.98, 1.04) among men and 1.07 (1.04, 1.10) among women. HRs were increased for cancer of the stomach (men, HR 1.23 [1.04, 1.46]; women, HR 1.78 [1.49, 2.13]), liver (men, HR 2.00 [1.67, 2.40]; women, HR 1.55 [1.14, 2.10]), pancreas (men, HR 1.53 [1.30, 1.79]; women, HR 1.25 [1.02,1.53]), endometrium (HR 1.42 [1.27, 1.58]) and kidney (men, HR 1.30 [1.12, 1.49]; women, HR 1.47 [1.23, 1.77]). Reduced HRs were found for cancer of the prostate (HR 0.56 [0.51, 0.61]) and breast (HR 0.90 [0.85, 0.94]). HRs declined with increasing diabetes duration. Type 1 diabetes was associated with differences in the risk of several common cancers; the strength of these associations varied with the duration of diabetes.
  • Kaapu, Kalle J.; Rantaniemi, Lauri; Talala, Kirsi; Taari, Kimmo; Tammela, Teuvo L. J.; Auvinen, Anssi; Murtola, Teemu J. (2018)
    In-vitro studies have suggested that the antiarrhythmic drug digoxin might restrain the growth of cancer cells by inhibiting Na+/K+-ATPase. We evaluated the association between cancer mortality and digoxin, sotalol and general antiarrhythmic drug use in a retrospective cohort study. The study population consists of 78,615 men originally identified for the Finnish Randomized Study of Screening for Prostate Cancer. Information on antiarrhythmic drug purchases was collected from the national prescription database. We used the Cox regression method to analyze separately overall cancer mortality and mortality from the most common types of cancer. During the median follow-up of 17.0 years after the baseline 28,936 (36.8%) men died, of these 8,889 due to cancer. 9,023 men (11.5%) had used antiarrhythmic drugs. Overall cancer mortality was elevated among antiarrhythmic drug users compared to non-users (HR 1.43, 95% CI 1.34-1.53). Similar results were observed separately for digoxin and for sotalol. However, the risk associations disappeared in long-term use and were modified by background co-morbidities. All in all, cancer mortality was elevated among antiarrhythmic drug users. This association is probably non-causal as it was related to short-term use and disappeared in long-term use. Our results do not support the anticancer effects of digoxin or any other antiarrhythmic drug.
  • Bitu, Carolina C.; Kauppila, Joonas H.; Bufalino, Andreia; Nurmenniemi, Sini; Teppo, Susanna; Keinanen, Meeri; Vilen, Suvi-Tuuli; Lehenkari, Petri; Nyberg, Pia; Coletta, Ricardo D.; Salo, Tuula (2013)
  • CIMBA Grp; Silvestri, Valentina; Leslie, Goska; Barnes, Daniel R.; Aittomäki, Kristiina; Nevanlinna, Heli (2020)
    Importance The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk reduction in this population. Objective To compare the cancer spectrum and frequencies between male BRCA1 and BRCA2 PV carriers. Design, Setting, and Participants Retrospective cohort study of 6902 men, including 3651 BRCA1 and 3251 BRCA2 PV carriers, older than 18 years recruited from cancer genetics clinics from 1966 to 2017 by 53 study groups in 33 countries worldwide collaborating through the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Clinical data and pathologic characteristics were collected. Main Outcomes and Measures BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview. Results Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. Being affected by any cancer was associated with a higher probability of being a BRCA2, rather than a BRCA1, PV carrier (OR, 3.23; 95% CI, 2.81-3.70; P <.001), as well as developing 2 (OR, 7.97; 95% CI, 5.47-11.60; P <.001) and 3 (OR, 19.60; 95% CI, 4.64-82.89; P <.001) primary tumors. A higher frequency of breast (OR, 5.47; 95% CI, 4.06-7.37; P <.001) and prostate (OR, 1.39; 95% CI, 1.09-1.78; P = .008) cancers was associated with a higher probability of being a BRCA2 PV carrier. Among cancers other than breast and prostate, pancreatic cancer was associated with a higher probability (OR, 3.00; 95% CI, 1.55-5.81; P = .001) and colorectal cancer with a lower probability (OR, 0.47; 95% CI, 0.29-0.78; P = .003) of being a BRCA2 PV carrier. Conclusions and Relevance Significant differences in the cancer spectrum were observed in male BRCA2, compared with BRCA1, PV carriers. These data may inform future recommendations for surveillance of BRCA1/2-associated cancers and guide future prospective studies for estimating cancer risks in men with BRCA1/2 PVs. This cohort study compares the cancer spectrum and frequencies between male BRCA1 and BRCA2 pathogenic variant carriers. Question Are there cancer phenotype differences between male BRCA1 and BRCA2 pathogenic variant carriers? Findings In this cohort study of 6902 men with a BRCA1 or BRCA2 pathogenic variant, being affected by cancer, particularly breast, prostate, and pancreatic cancers and developing multiple primary tumors, was associated with a higher probability for a man of being a BRCA2, rather than a BRCA1, pathogenic variant carrier. Meaning Surveillance programs in men with BRCA1 and BRCA2 pathogenic variants should be tailored in light of these gene-specific cancer phenotype differences. These results may inform the design of prospective studies on cancer risks in male BRCA1 and BRCA2 pathogenic variant carriers.
  • Landais, Edwige; Moskal, Aurelie; Mullee, Amy; Nicolas, Genevieve; Gunter, Marc J.; Huybrechts, Inge; Overvad, Kim; Roswall, Nina; Affret, Aurelie; Fagherazzi, Guy; Mahamat-Saleh, Yahya; Katzke, Verena; Kuehn, Tilman; La Vecchia, Carlo; Trichopoulou, Antonia; Valanou, Elissavet; Saieva, Calogero; de Magistris, Maria Santucci; Sieri, Sabina; Braaten, Tonje; Skeie, Guri; Weiderpass, Elisabete; Ardanaz, Eva; Chirlaque, Maria-Dolores; Garcia, Jose Ramon; Jakszyn, Paula; Rodriguez-Barranco, Miguel; Brunkwall, Louise; Huseinovic, Ena; Nilsson, Lena; Wallstroem, Peter; Bueno-de-Mesquita, Bas; Peeters, Petra H.; Aune, Dagfinn; Key, Tim; Lentjes, Marleen; Riboli, Elio; Slimani, Nadia; Freisling, Heinz (2018)
    Background: Coffee and tea are among the most commonly consumed nonalcoholic beverages worldwide, but methodological differences in assessing intake often hamper comparisons across populations. We aimed to (i) describe coffee and tea intakes and (ii) assess their contribution to intakes of selected nutrients in adults across 10 European countries. Method: Between 1995 and 2000, a standardized 24-h dietary recall was conducted among 36,018 men and women from 27 European Prospective Investigation into Cancer and Nutrition (EPIC) study centres. Adjusted arithmetic means of intakes were estimated in grams (=volume) per day by sex and centre. Means of intake across centres were compared by sociodemographic characteristics and lifestyle factors. Results: In women, the mean daily intake of coffee ranged from 94 g/day (similar to 0.6 cups) in Greece to 781 g/day (similar to 4.4 cups) in Aarhus (Denmark), and tea from 14 g/day (similar to 0.1 cups) in Navarra (Spain) to 788 g/day (similar to 4.3 cups) in the UK general population. Similar geographical patterns for mean daily intakes of both coffee and tea were observed in men. Current smokers as compared with those who reported never smoking tended to drink on average up to 500 g/day more coffee and tea combined, but with substantial variation across centres. Other individuals' characteristics such as educational attainment or age were less predictive. In all centres, coffee and tea contributed to less than 10% of the energy intake. The greatest contribution to total sugar intakes was observed in Southern European centres (up to similar to 20%). Conclusion: Coffee and tea intake and their contribution to energy and sugar intake differed greatly among European adults. Variation in consumption was mostly driven by geographical region.
  • Omoruyi, Iyekhoetin Matthew; Ahamioje, Derek; Pohjanvirta, Raimo (2014)
  • Spjuth, Ola; Karlsson, Andreas; Clements, Mark; Humphreys, Keith; Ivansson, Emma; Dowling, Jim; Eklund, Martin; Jauhiainen, Alexandra; Czene, Kamila; Gronberg, Henrik; Sparen, Par; Wiklund, Fredrik; Cheddad, Abbas; Palsdottir, Porgerodur; Rantalainen, Mattias; Abrahamsson, Linda; Laure, Erwin; Litton, Jan-Eric; Palmgren, Juni (2017)
    Objective: We provide an e-Science perspective on the workflow from risk factor discovery and classification of disease to evaluation of personalized intervention programs. As case studies, we use personalized prostate and breast cancer screenings. Materials and Methods: We describe an e-Science initiative in Sweden, e-Science for Cancer Prevention and Control (eCPC), which supports biomarker discovery and offers decision support for personalized intervention strategies. The generic eCPC contribution is a workflow with 4 nodes applied iteratively, and the concept of e-Science signifies systematic use of tools from the mathematical, statistical, data, and computer sciences. Results: The eCPC workflow is illustrated through 2 case studies. For prostate cancer, an in-house personalized screening tool, the Stockholm-3 model (S3M), is presented as an alternative to prostate-specific antigen testing alone. S3M is evaluated in a trial setting and plans for rollout in the population are discussed. For breast cancer, new biomarkers based on breast density and molecular profiles are developed and the US multicenter Women Informed to Screen Depending on Measures (WISDOM) trial is referred to for evaluation. While current eCPC data management uses a traditional data warehouse model, we discuss eCPC-developed features of a coherent data integration platform. Discussion and Conclusion: E-Science tools are a key part of an evidence-based process for personalized medicine. This paper provides a structured workflow from data and models to evaluation of new personalized intervention strategies. The importance of multidisciplinary collaboration is emphasized. Importantly, the generic concepts of the suggested eCPC workflow are transferrable to other disease domains, although each disease will require tailored solutions.
  • Hemminki, Kari; Sundquist, Kristina; Sundquist, Jan; Försti, Asta; Hemminki, Akseli; Li, Xinjun (2021)
    Simple Summary Familial cancer can be defined through the occurrence of the same cancer in two or more family members. Hereditary cancer is a narrower definition of high-risk familial aggregation through identified predisposing genes. The absence of correlation between spouses for risk of most cancers, particularly those not related to tobacco smoking or solar exposure, suggests that familial cancers are mainly due to genetic causes. The aim of the present study was to define the frequency and increased risk for familial cancer. Data on 31 of the most common cancers were obtained from the Swedish Family-Cancer Database and familial relative risks (SIRs) were estimated between persons with or without family history of the same cancer in first-degree relatives. Practically all cancers showed a familial risk, with an SIR most commonly around two, or a doubling of the risk because of family history. Background: Familial cancer can be defined through the occurrence of the same cancer in two or more family members. We describe a nationwide landscape of familial cancer, including its frequency and the risk that it conveys, by using the largest family database in the world with complete family structures and medically confirmed cancers. Patients/methods: We employed standardized incidence ratios (SIRs) to estimate familial risks for concordant cancer among first-degree relatives using the Swedish Cancer Registry from years 1958 through 2016. Results: Cancer risks in a 20-84 year old population conferred by affected parents or siblings were about two-fold compared to the risk for individuals with unaffected relatives. For small intestinal, testicular, thyroid and bone cancers and Hodgkin disease, risks were higher, five-to-eight-fold. Novel familial associations included adult bone, lip, pharyngeal, and connective tissue cancers. Familial cancers were found in 13.2% of families with cancer; for prostate cancer, the proportion was 26.4%. High-risk families accounted for 6.6% of all cancer families. Discussion/Conclusion: High-risk family history should be exceedingly considered for management, including targeted genetic testing. For the major proportion of familial clustering, where genetic testing may not be feasible, medical and behavioral intervention should be indicated for the patient and their family members, including screening recommendations and avoidance of carcinogenic exposure.
  • Wei, Gong-Hong; Badis, Gwenael; Berger, Michael F.; Kivioja, Teemu; Palin, Kimmo; Enge, Martin; Bonke, Martin; Jolma, Arttu; Varjosalo, Markku; Gehrke, Andrew R.; Yan, Jian; Talukder, Shaheynoor; Turunen, Mikko; Taipale, Mikko; Stunnenberg, Hendrik G.; Ukkonen, Esko; Hughes, Timothy R.; Bulyk, Martha L.; Taipale, Jussi (2010)
  • Habermann, Jens K.; Buendgen, Nana K.; Gemoll, Timo; Hautaniemi, Sampsa; Lundgren, Caroline; Wangsa, Danny; Doering, Jana; Bruch, Hans-Peter; Nordstroem, Britta; Roblick, Uwe J.; Jornvall, Hans; Auer, Gert; Ried, Thomas (2011)
  • Belitskin, Denis; Pant, Shishir M.; Munne, Pauliina; Suleymanova, Ilida; Belitskina, Kati; Ala-Hongisto, Hanna; Englund, Johanna; Raatikainen, Tiina; Klezovitch, Olga; Vasioukhin, Valeri; Li, Shuo; Wu, Qingyu; Monni, Outi; Kuure, Satu; Laakkonen, Pirjo; Pouwels, Jeroen; Tervonen, Topi A.; Klefström, Juha (2021)
    Transforming growth factor-beta (TGF beta) is a multifunctional cytokine with a well-established role in mammary gland development and both oncogenic and tumor-suppressive functions. The extracellular matrix (ECM) indirectly regulates TGF beta activity by acting as a storage compartment of latent-TGF beta, but how TGF beta is released from the ECM via proteolytic mechanisms remains largely unknown. In this study, we demonstrate that hepsin, a type II transmembrane protease overexpressed in 70% of breast tumors, promotes canonical TGF beta signaling through the release of latent-TGF beta from the ECM storage compartment. Mammary glands in hepsin CRISPR knockout mice showed reduced TGF beta signaling and increased epithelial branching, accompanied by increased levels of fibronectin and latent-TGF beta 1, while overexpression of hepsin in mammary tumors increased TGF beta signaling. Cell-free and cell-based experiments showed that hepsin is capable of direct proteolytic cleavage of fibronectin but not latent-TGF beta and, importantly, that the ability of hepsin to activate TGF beta signaling is dependent on fibronectin. Altogether, this study demonstrates a role for hepsin as a regulator of the TGF beta pathway in the mammary gland via a novel mechanism involving proteolytic downmodulation of fibronectin.
  • Salo, Sirpa; Bitu, Carolina; Merkku, Kalle; Nyberg, Pia; Bello, Ibrahim O.; Vuoristo, Jussi; Sutinen, Meeri; Vahanikkila, Hannu; Costea, Daniela E.; Kauppila, Joonas; Lehenkari, Petri; Dayan, Dan; Vered, Marilena; Risteli, Juha; Salo, Tuula (2013)
  • Palviainen, Mari; Saari, Heikki; Kärkkäinen, Olli; Pekkinen, Jenna; Auriola, Seppo; Yliperttula, Marjo; Puhka, Maija; Hanhineva, Kati; Siljander, Pia R-M (2019)
    One of the greatest bottlenecks in extracellular vesicle (EV) research is the production of sufficient material in a consistent and effective way using in vitro cell models. Although the production of EVs in bioreactors maximizes EV yield in comparison to conventional cell cultures, the impact of their cell growth conditions on EVs has not yet been established. In this study, we grew two prostate cancer cell lines, PC-3 and VCaP, in conventional cell culture dishes and in two-chamber bioreactors to elucidate how the growth environment affects the EV characteristics. Specifically, we wanted to investigate the growth condition-dependent differences by non-targeted metabolite profiling using liquid chromatography-mass spectrometry (LC-MS) analysis. EVs were also characterized by their morphology, size distribution, and EV protein marker expression, and the EV yields were quantified by NTA. The use of bioreactor increased the EV yield >100 times compared to the conventional cell culture system. Regarding morphology, size distribution and surface markers, only minor differences were observed between the bioreactor-derived EVs (BR-EVs) and the EVs obtained from cells grown in conventional cell cultures (C-EVs). In contrast, metabolomic analysis revealed statistically significant differences in both polar and non-polar metabolites when the BR-EVs were compared to the C-EVs. The results show that the growth conditions markedly affected the EV metabolite profiles and that metabolomics was a sensitive tool to study molecular differences of EVs. We conclude that the cell culture conditions of EV production should be standardized and carefully detailed in publications and care should be taken when EVs from different production platforms are compared with each other for systemic effects.
  • Thery, Clotilde; Witwer, Kenneth W.; Aikawa, Elena; Jose Alcaraz, Maria; Anderson, Johnathon D.; Andriantsitohaina, Ramaroson; Antoniou, Anna; Arab, Tanina; Archer, Fabienne; Atkin-Smith, Georgia K.; Ayre, D. Craig; Bach, Jean-Marie; Bachurski, Daniel; Baharvand, Hossein; Balaj, Leonora; Baldacchino, Shawn; Bauer, Natalie N.; Baxter, Amy A.; Bebawy, Mary; Beckham, Carla; Zavec, Apolonija Bedina; Benmoussa, Abderrahim; Berardi, Anna C.; Bergese, Paolo; Bielska, Ewa; Blenkiron, Cherie; Bobis-Wozowicz, Sylwia; Boilard, Eric; Boireau, Wilfrid; Bongiovanni, Antonella; Borras, Francesc E.; Bosch, Steffi; Boulanger, Chantal M.; Breakefield, Xandra; Breglio, Andrew M.; Brennan, Meadhbh A.; Brigstock, David R.; Brisson, Alain; Broekman, Marike L. D.; Bromberg, Jacqueline F.; Bryl-Gorecka, Paulina; Buch, Shilpa; Buck, Amy H.; Burger, Dylan; Busatto, Sara; Buschmann, Dominik; Bussolati, Benedetta; Buzas, Edit; Byrd, James Bryan; Camussi, Giovanni; Carter, David R. F.; Caruso, Sarah; Chamley, Lawrence W.; Chang, Yu-Ting; Chaudhuri, Amrita Datta; Chen, Chihchen; Chen, Shuai; Cheng, Lesley; Chin, Andrew R.; Clayton, Aled; Clerici, Stefano P.; Cocks, Alex; Cocucci, Emanuele; Coffey, Robert J.; Cordeiro-da-Silva, Anabela; Couch, Yvonne; Coumans, Frank A. W.; Coyle, Beth; Crescitelli, Rossella; Criado, Miria Ferreira; D'Souza-Schorey, Crislyn; Das, Saumya; de Candia, Paola; De Santana Junior, Eliezer F.; De Wever, Olivier; del Portillo, Hernando A.; Demaret, Tanguy; Deville, Sarah; Devitt, Andrew; Dhondt, Bert; Di Vizio, Dolores; Dieterich, Lothar C.; Dolo, Vincenza; Dominguez Rubio, Ana Paula; Dominici, Massimo; Dourado, Mauricio R.; Driedonks, Tom A. P.; Duarte, Filipe; Duncan, Heather M.; Eichenberger, Ramon M.; Ekstrom, Karin; Andaloussi, Samir E. L.; Elie-Caille, Celine; Erdbrugger, Uta; Falcon-Perez, Juan M.; Fatima, Farah; Fish, Jason E.; Flores-Bellver, Miguel; Forsonits, Andras; Frelet-Barrand, Annie; Fricke, Fabia; Fuhrmann, Gregor; Gabrielsson, Susanne; Gamez-Valero, Ana; Gardiner, Chris; Gaertner, Kathrin; Gaudin, Raphael; Gho, Yong Song; Giebel, Bernd; Gilbert, Caroline; Gimona, Mario; Giusti, Ilaria; Goberdhan, Deborah C.; Goergens, Andre; Gorski, Sharon M.; Greening, David W.; Gross, Julia Christina; Gualerzi, Alice; Gupta, Gopal N.; Gustafson, Dakota; Handberg, Aase; Haraszti, Reka A.; Harrison, Paul; Hegyesi, Hargita; Hendrix, An; Hill, Andrew F.; Hochberg, Fred H.; Hoffmann, Karl F.; Holder, Beth; Holthofer, Harry; Hosseinkhani, Baharak; Hu, Guoku; Huang, Yiyao; Huber, Veronica; Hunt, Stuart; Ibrahim, Ahmed Gamal-Eldin; Ikezu, Tsuneya; Inal, Jameel M.; Isin, Mustafa; Ivanova, Alena; Jackson, Hannah K.; Jacobsen, Soren; Jay, Steven M.; Jayachandran, Muthuvel; Jenster, Guido; Jiang, Lanzhou; Johnson, Suzanne M.; Jones, Jennifer C.; Jong, Ambrose; Jovanovic-Talisman, Tijana; Jung, Stephanie; Kalluri, Raghu; Kano, Shin-ichi; Kaur, Sukhbir; Kawamura, Yumi; Keller, Evan T.; Khamari, Delaram; Khomyakova, Elena; Khvorova, Anastasia; Kierulf, Peter; Kim, Kwang Pyo; Kislinger, Thomas; Klingeborn, Mikael; Klinke, David J.; Kornek, Miroslaw; Kosanovic, Maja M.; Kovacs, Arpad Ferenc; Kraemer-Albers, Eva-Maria; Krasemann, Susanne; Krause, Mirja; Kurochkin, Igor; Kusuma, Gina D.; Kuypers, Soren; Laitinen, Saara; Langevin, Scott M.; Languino, Lucia R.; Lannigan, Joanne; Lasser, Cecilia; Laurent, Louise C.; Lavieu, Gregory; Lazaro-Ibanez, Elisa; Le Lay, Soazig; Lee, Myung-Shin; Lee, Yi Xin Fiona; Lemos, Debora S.; Lenassi, Metka; Leszczynska, Aleksandra; Li, Isaac T. S.; Liao, Ke; Libregts, Sten F.; Ligeti, Erzsebet; Lim, Rebecca; Lim, Sai Kiang; Line, Aija; Linnemannstoens, Karen; Llorente, Alicia; Lombard, Catherine A.; Lorenowicz, Magdalena J.; Lorincz, Akos M.; Lotvall, Jan; Lovett, Jason; Lowry, Michelle C.; Loyer, Xavier; Lu, Quan; Lukomska, Barbara; Lunavat, Taral R.; Maas, Sybren L. N.; Malhi, Harmeet; Marcilla, Antonio; Mariani, Jacopo; Mariscal, Javier; Martens-Uzunova, Elena S.; Martin-Jaular, Lorena; Martinez, M. Carmen; Martins, Vilma Regina; Mathieu, Mathilde; Mathivanan, Suresh; Maugeri, Marco; McGinnis, Lynda K.; McVey, Mark J.; Meckes, David G.; Meehan, Katie L.; Mertens, Inge; Minciacchi, Valentina R.; Moller, Andreas; Jorgensen, Malene Moller; Morales-Kastresana, Aizea; Morhayim, Jess; Mullier, Francois; Muraca, Maurizio; Musante, Luca; Mussack, Veronika; Muth, Dillon C.; Myburgh, Kathryn H.; Najrana, Tanbir; Nawaz, Muhammad; Nazarenko, Irina; Nejsum, Peter; Neri, Christian; Neri, Tommaso; Nieuwland, Rienk; Nimrichter, Leonardo; Nolan, John P.; Hoen, Esther N. M. Nolte-'t; Hooten, Nicole Noren; O'Driscoll, Lorraine; O'Grady, Tina; O'Loghlen, Ana; Ochiya, Takahiro; Olivier, Martin; Ortiz, Alberto; Ortiz, Luis A.; Osteikoetxea, Xabier; Ostegaard, Ole; Ostrowski, Matias; Park, Jaesung; Pegtel, D. Michiel; Peinado, Hector; Perut, Francesca; Pfaffl, Michael W.; Phinney, Donald G.; Pieters, Bartijn C. H.; Pink, Ryan C.; Pisetsky, David S.; von Strandmann, Elke Pogge; Polakovicova, Iva; Poon, Ivan K. H.; Powell, Bonita H.; Prada, Ilaria; Pulliam, Lynn; Quesenberry, Peter; Radeghieri, Annalisa; Raffai, Robert L.; Raimondo, Stefania; Rak, Janusz; Ramirez, Marcel; Raposo, Graca; Rayyan, Morsi S.; Regev-Rudzki, Neta; Ricklefs, Franz L.; Robbins, Paul D.; Roberts, David D.; Rodrigues, Silvia C.; Rohde, Eva; Rome, Sophie; Rouschop, Kasper M. A.; Rughetti, Aurelia; Russell, Ashley E.; Saa, Paula; Sahoo, Susmita; Salas-Huenuleo, Edison; Sanchez, Catherine; Saugstad, Julie A.; Saul, Meike J.; Schiffelers, Raymond M.; Schneider, Raphael; Schoyen, Tine Hiorth; Scott, Aaron; Shahaj, Eriomina; Sharma, Shivani; Shatnyeva, Olga; Shekari, Faezeh; Shelke, Ganesh Vilas; Shetty, Ashok K.; Shiba, Kiyotaka; Siljander, Pia R-M; Silva, Andreia M.; Skowronek, Agata; Snyder, Orman L.; Soares, Rodrigo Pedro; Sodar, Barbara W.; Soekmadji, Carolina; Sotillo, Javier; Stahl, Philip D.; Stoorvogel, Willem; Stott, Shannon L.; Strasser, Erwin F.; Swift, Simon; Tahara, Hidetoshi; Tewari, Muneesh; Timms, Kate; Tiwari, Swasti; Tixeira, Rochelle; Tkach, Mercedes; Toh, Wei Seong; Tomasini, Richard; Torrecilhas, Ana Claudia; Pablo Tosar, Juan; Toxavidis, Vasilis; Urbanelli, Lorena; Vader, Pieter; van Balkom, Bas W. M.; van der Grein, Susanne G.; Van Deun, Jan; van Herwijnen, Martijn J. C.; Van Keuren-Jensen, Kendall; van Niel, Guillaume; van Royen, Martin E.; van Wijnen, Andre J.; Helena Vasconcelos, M.; Vechetti, Ivan J.; Veit, Tiago D.; Vella, Laura J.; Velot, Emilie; Verweij, Frederik J.; Vestad, Beate; Vinas, Jose L.; Visnovitz, Tamas; Vukman, Krisztina V.; Wahlgren, Jessica; Watson, Dionysios C.; Wauben, Marca H. M.; Weaver, Alissa; Webber, Jason P.; Weber, Viktoria; Wehman, Ann M.; Weiss, Daniel J.; Welsh, Joshua A.; Wendt, Sebastian; Wheelock, Asa M.; Wiener, Zoltan; Witte, Leonie; Wolfram, Joy; Xagorari, Angeliki; Xander, Patricia; Xu, Jing; Yan, Xiaomei; Yanez-Mo, Maria; Yin, Hang; Yuana, Yuana; Zappulli, Valentina; Zarubova, Jana; Zekas, Vytautas; Zhang, Jian-ye; Zhao, Zezhou; Zheng, Lei; Zheutlin, Alexander R.; Zickler, Antje M.; Zimmermann, Pascale; Zivkovic, Angela M.; Zocco, Davide; Zuba-Surma, Ewa K. (2018)
    The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines for the field in 2014. We now update these "MISEV2014" guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
  • Koski, Anniina; Karli, Eerika; Kipar, Anja; Escutenaire, Sophie; Kanerva, Anna-Maija; Hemminki, Akseli (2013)